China Pharma Holdings (CPHI) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.
- China Pharma Holdings' Consolidated Net Income rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3276.23%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
- Latest data reveals that China Pharma Holdings reported Consolidated Net Income of -$651482.0 as of Q3 2025, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
- In the past 5 years, China Pharma Holdings' Consolidated Net Income ranged from a high of -$475976.0 in Q1 2023 and a low of -$1.4 million during Q2 2024
- For the 5-year period, China Pharma Holdings' Consolidated Net Income averaged around -$902785.3, with its median value being -$826669.0 (2021).
- In the last 5 years, China Pharma Holdings' Consolidated Net Income crashed by 641855.51% in 2021 and then skyrocketed by 6326.01% in 2025.
- Quarter analysis of 5 years shows China Pharma Holdings' Consolidated Net Income stood at -$980719.0 in 2021, then dropped by 28.9% to -$1.3 million in 2022, then increased by 2.53% to -$1.2 million in 2023, then increased by 0.63% to -$1.2 million in 2024, then soared by 46.79% to -$651482.0 in 2025.
- Its Consolidated Net Income stands at -$651482.0 for Q3 2025, versus -$528367.0 for Q2 2025 and -$785572.0 for Q1 2025.